Disease Landscape and Forecast Insights

Multiple treatment options—topical therapies, oral drugs, phototherapy, and biologics—are available to treat psoriasis. In particular, the approval of biologics other than TNF-α inhibitors (…

Cancer pain is a complex form of chronic pain to treat because it typically involves mixed nociceptive and neuropathic pain resulting from multiple causes (e.g., chemotherapy, metastases)…

Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just in the past year…

The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has resulted in a highly segmented space dominated by…

The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and…

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g.,…

Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist, physicians, patients, and healthcare systems have concerns about their limitations. Delivery…

Patients with diabetic retinopathy (DR) experience retinal damage that can lead to vision impairment and eventual blindness, especially with the development of diabetic macular edema (DME). DME…

The highly genericized biguanides and sulfonylureas are, by far, the most heavily prescribed type 2 diabetes (T2D) drug classes. However, branded agents from several drug classes are jostling for…

The bladder cancer market has seen a tremendous uptake of immune checkpoint inhibitors with their approval in the locally advanced / metastatic setting and, in the case of Merck & Co.’s Keytruda…

Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination regimens,…

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the…